Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population
@article{Aro1991CardiovascularAA, title={Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population}, author={Jussi Aro}, journal={The Prostate}, year={1991}, volume={18} }
Four hundred and seventy‐seven prospectively randomized patients with prostatic carcinoma were treated with a combination of intramuscular polyestradiol phosphate (PEP) and oral ethinyl estradiol, with intramuscular PEP alone, or with orchiectomy. The cardiovascular and all‐cause mortality of the two estrogen therapy modalities and orchiectomy were compared with those of the Finnish male population in general. The age‐standardized rate ratios (∼ relative risk) for cardiovascular mortality and…
25 Citations
Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
- MedicineBritish journal of urology
- 1998
Parenteral PEP (240 mg/month) seems to be as efficient as orchidectomy in inhibiting disease in patients with advanced prostatic cancer, and the difference was statistically significant during the first year of treatment.
Gastrectomy for Early Gastric Cancer is Associated with Decreased Cardiovascular Mortality in Association with Postsurgical Metabolic Changes
- MedicineAnnals of Surgical Oncology
- 2012
Patients with EGC who undergo gastrectomy have a lower cardiovascular mortality but similar all-cause mortality as that of the general population, and a significant reduction in body weight and visceral fat after surgery may improve impaired lipid metabolism and prevent atherosclerotic changes.
Transdermal estradiol therapy for advanced prostate cancer--forward to the past?
- Medicine, BiologyThe Journal of urology
- 2003
Transdermal estradiol therapy prevented andropause symptoms, improved quality of life scores and increased bone density, with the potential for considerable economic savings over conventional hormone therapies.
Advanced Prostate Cancer
- Medicine, BiologyEuropean Urology
- 2001
The aim of intermittent androgen suppression is to increase quality of life during treatment-free periods and to maintain the androgen dependency of the malignant cells.
Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy
- Medicine, BiologyNature Clinical Practice Oncology
- 2006
Parenteral estrogen therapy has the advantage of giving protection against the effects of andropause, which are induced by conventional androgen suppression and include osteoporotic fracture, hot flashes, asthenia and cognitive dysfunction.
Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study.
- Medicine, BiologyScandinavian journal of urology and nephrology
- 1994
In locally advanced (M0) and histologically well or moderately differentiated tumours, LHRH agonist therapy was considerably more effective than oestrogen as regards time to progression of the carcinoma, but in metastatic (M1) and Histologically poorly differentiated tumour both methods gave similar results.
Review Article ESTROGENS IN THE TREATMENT OF PROSTATE CANCER
- Medicine
- 1998
Comparing the efficacy, complications and cost of regimens containing oral estrogens or parented estrogens with agents that increase efficacy and decrease toxicity to results of other regimens, such as combined androgen blockade, should be done to determine if an estrogencontaining regimen could lower the cost of treating advanced prostate cancer.
androgen deprivation therapy for prostate cancer - the potential of parenteral estrogen
- Medicine, Biology
- 2009
Parenteral estrogen therapy is protection against the effects of the andropause (cf female menopause), which with conventional androgen suppression causes significant morbidity including osteoporotic fracture, hot flushes, lethargy and cognitive dysfunction.
References
SHOWING 1-10 OF 23 REFERENCES
Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
- Medicine, BiologyScandinavian journal of urology and nephrology. Supplementum
- 1980
Cardiovascular complications categorized as impaired arterial circulation including ischemic heart disease, venous thromboembolism, cardiac incompensation and cerebral depression were found to be equally frequent following the two different forms of treatment.
Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.
- Medicine
- 1986
The substantially increased risk of cardiovascular complications in patients given oestrogen for prostatic cancer warrants careful consideration when choosing treatment for this disorder.
Cardiovascular complications in the treatment of prostatic carcinoma.
- MedicineBritish journal of urology
- 1981
It is recommended that stilboestrol and estramustine phosphate should not be used in the presence of cardiovascular disease and that the primary form of treatment in prostatic carcinoma should be bilateral orchiectomy, especially in patients with localised disease.
Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate
- MedicineCancer
- 1970
Patients treated with a 5.0‐mg daily dose of diethylstilbestrol (DES) had an increased incidence of fatal and non‐fatal cardiovascular disease when compared to placebo in all stages of prostatic…
Treatment of prostatic carcinoma with polyestradiol phosphate combined with ethinylestradiol.
- MedicineScandinavian journal of urology and nephrology
- 1971
Combined treatment with Estradurin and a stronger inhibitor of gonadotropin might be more effective in patients with prostatic carcinoma, which has a firm diagnosis of carcinoma.
Comparison of endocrine and radiation therapy in locally advanced prostatic cancer.
- MedicineEuropean urology
- 1988
During the 4-year follow-up period there were no significant differences in the progression rates and the frequency of thromboembolic and other cardiovascular complications was highest in the estrogen group, while in the radiotherapy group, 19 of 45 patients had bowel or bladder complications.
Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate
- Medicine, BiologyThe Prostate
- 1988
Patients with cancer of the prostate treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections have responded to therapy and there have been no cardiovascular complications at a mean follow‐up of 12.9 ± 0.7 months.
Hormonal Therapy of Prostatic Cancer
- MedicineCancer
- 1980
Three VACURG studies report that patients with low stage disease who are treated with estrogen have a higher death rate than men not receiving estrogen and in patients with high stage disease, delayed hormonal therapy is as effective as early hormonal therapy.
Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.
- Medicine, BiologyEuropean urology
- 1990
PEP treatment caused changes in the serum lipoprotein pattern, which apparently decreases the risk of atherosclerosis.
High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
- MedicineBritish journal of urology
- 1989
It was concluded that parenteral high dose PEP is not associated with an increased risk of cardiovascular complications and there is no need for daily low dose ASA.